Intuitive Surgical (NASDAQ:ISRG) Given New $502.00 Price Target at Leerink Partners

Intuitive Surgical (NASDAQ:ISRG) had its price objective lifted by Leerink Partners from $489.00 to $502.00 in a research report released on Thursday morning.

Other equities research analysts have also issued reports about the stock. Robert W. Baird lifted their price target on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday. Evercore ISI boosted their target price on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Citigroup increased their price target on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Finally, Piper Sandler lifted their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $521.15 on Thursday. Intuitive Surgical has a 52-week low of $254.85 and a 52-week high of $523.34. The firm has a market cap of $184.85 billion, a price-to-earnings ratio of 94.07, a PEG ratio of 5.40 and a beta of 1.39. The business’s fifty day moving average is $483.85 and its 200-day moving average is $438.56.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 earnings per share. As a group, research analysts forecast that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at $145,113.45. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $5,441,507.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently made changes to their positions in the stock. Mirador Capital Partners LP raised its stake in Intuitive Surgical by 1.4% during the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after buying an additional 50 shares during the period. Advisors Asset Management Inc. raised its position in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after purchasing an additional 76,649 shares in the last quarter. Brookstone Capital Management grew its position in Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after purchasing an additional 2,289 shares during the period. Finally, M&G Plc increased its stake in Intuitive Surgical by 53.5% during the 2nd quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after purchasing an additional 1,766 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.